Skip to main content

MDRPEDIA RECORDTITAN · TIER ILIVING

Dennis Slamon

Oncology (Breast Cancer) · University of California, Los Angeles · Los Angeles, United States

Suggest a correction
TITAN · TIER I · MDRPEDIA · LISTED ·MTIER I
h-index (OpenAlex)
130
Papers on record
10
Citations to these papers
45,968
Stature
Tier I
EVIDENCE RECORD

What this record is built on

Compared with the register: Surgery · United States · How it works

I · SCHOLARSHIP

h-index
130 · 88th pct
OpenAlex✓ Verified
Papers on record
10
Crossref / DOI◐ Public record
Citations received
45,968
OpenAlex◐ Public record

II · PRACTICE

Licence
Not yet checked
Medical council○ Not reported
Board certification
—
Specialty boards○ Not reported
Registration ID
—
National registry○ Not reported
Institutions
2
Institution records◐ Public record

III · LEARNING & TEACHING

Trainees traced
Not yet traced
Lineage○ Not reported
Mentors traced
Not yet traced
Lineage○ Not reported
Invited talks
—
Congress programmes○ Not reported

IV · PEER STANDING

Honours
2
Awarding bodies◐ Public record
Techniques pioneered
1
Published literature◐ Public record
Ethics mark
Not yet audited
MDRPedia audit○ Not reported

Not on this record by design:Star ratingsAnonymous reviewsPaid placement

Record

Dennis Slamon is an American oncologist who discovered the role of the HER2 gene in aggressive breast cancer and developed trastuzumab (Herceptin), a targeted therapy that has saved hundreds of thousands of lives. He is chief of hematology-oncology at UCLA.
IN PLAIN WORDS
  • Pioneered the HER2-targeted therapy with trastuzumab (Herceptin), a technique still used by doctors worldwide
  • Research is cited 46K+ times by other doctors and scientists, indicating significant influence on medical research
  • Currently at University of California, Los Angeles in Los Angeles, United States

Institutions

  • University of California, Los AngelesChief of Hematology-Oncology
  • Jonsson Comprehensive Cancer CenterDirector of Clinical and Translational Research
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
  • Is a procedure needed now, or can medicines and lifestyle changes help first?
  • What are the risks and benefits of each option for someone like me?
  • How many similar cases does your team see, and who will be involved in my care?
  • Who do I contact if symptoms come back after treatment?

Landmark papers

Papers on record
10
Citations received
45,968
Papers on record by year, 1987–2016

PUBLISHED IN Science · New England Journal of Medicine · Journal of Clinical Oncology · Cell · The Lancet Oncology

  1. 1987Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>OncogeneSciencedoi 10.1126/science.379810611,702 citations
  2. 2001Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicinedoi 10.1056/nejm20010315344110111,460 citations
  3. 1989Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian CancerSciencedoi 10.1126/science.24701526,845 citations
  4. 2016Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicinedoi 10.1056/nejmoa16073032,903 citations
  5. 1999Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncologydoi 10.1200/jco.1999.17.9.26392,788 citations
Show all 10 papersShow fewer papers
  1. 2011Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicinedoi 10.1056/nejmoa09103832,756 citations
  2. 2015Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCelldoi 10.1016/j.cell.2015.07.0111,955 citations
  3. 2014The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncologydoi 10.1016/s1470-2045(14)71159-31,899 citations
  4. 2002Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast CancerJournal of Clinical Oncologydoi 10.1200/jco.2002.20.3.7191,854 citations
  5. 2016Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncologydoi 10.1016/s1470-2045(15)00613-01,806 citations

Honours

  • —Lasker-DeBakey Clinical Medical Research Award (2019)
  • —Dickson Prize in Medicine

Techniques pioneered

  • HER2-targeted therapy with trastuzumab (Herceptin)

Career

  • 1987Published HER2 discoveryPublished landmark paper linking HER2 gene amplification to aggressive breast cancer
  • 1998FDA approved trastuzumab (Herceptin)Herceptin became the first HER2-targeted therapy approved for breast cancer
  • 2012FDA approved ado-trastuzumab emtansineNext-generation antibody-drug conjugate T-DM1 (Kadcyla) approved
  • 2019Lasker AwardReceived the Lasker-DeBakey Clinical Medical Research Award for HER2 work

Training and certification

  • University of Chicago

Lineage

We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR

Are you Dennis Slamon?

Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.

Share this record

Share card for Dennis Slamon